On July 25th, Golonghui reported that Tonghua Dongbao (600867.SH) stated on the interactive platform that in the continuation of the centralized procurement bidding, the company acquired more than 30% of the national secondary distribution, about 10 million units. At the same time, there has been a significant improvement and breakthrough in the hospital access of insulin analogs, including about 1,400 newly admitted hospitals for glycine insulin and about 3,000 newly admitted hospitals for Menodan insulin. Additionally, about 5,000 newly admitted hospitals for premixed Menodan insulin. Furthermore, the company will continue to increase investment in grassroots markets, retail channels, private hospitals, and other non-standard markets to expand the incremental space.
Clear
All
Quotes
News
Learn
Help
All
US
HK
CN
SG
AU
JP
All
News
Announcements
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
通化东宝(600867.SH):预混型门冬胰岛素新增准入约5000家医院
Tonghua Dongbao Pharmaceutical (600867.SH): The newly approved pre-mixed insulin has been added to about 5000 hospitals.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Like
Views 298
Write a comment
Statement
This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report